Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAM01 for Malaria Prevention in African Adults and Children
NCT06408857Phase 1Completed
- Sponsor
- Gates Medical Research Institute
- Start
- Mar 2025
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MAM01 in malaria (11 cohorts), sponsored by Gates Medical Research Institute. Primary endpoints: Number of participants reporting Treatment-emergent adverse events at 28 days, Number of participants reporting serious adverse events, adverse events of special interest, and AEs leading to discontinuation at 182 days and 2 more. Started Mar 2025; status: completed.
02
Drugs
MAM01
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06408857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06408857.